Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
Abstract
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT2A agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North America. Members of these groups typically ingest ayahuasca at least twice per month. Prior research has shown that acute ayahuasca increases blood flow in prefrontal and temporal brain regions and that it elicits intense modifications in thought processes, perception and emotion. However, regular ayahuasca use does not seem to induce the pattern of addiction-related problems that characterize drugs of abuse. To study the impact of repeated ayahuasca use on general psychological well-being, mental health and cognition, here we assessed personality, psychopathology, life attitudes and neuropsychological performance in regular ayahuasca users (n = 127) and controls (n = 115) at baseline and 1 year later. Controls were actively participating in non-ayahuasca religions. Users showed higher Reward Dependence and Self-Transcendence and lower Harm Avoidance and Self-Directedness. They scored significantly lower on all psychopathology measures, showed better performance on the Stroop test, the Wisconsin Card Sorting Test and the Letter-Number Sequencing task from the WAIS-III, and better scores on the Frontal Systems Behavior Scale. Analysis of life attitudes showed higher scores on the Spiritual Orientation Inventory, the Purpose in Life Test and the Psychosocial Well-Being test. Despite the lower number of participants available at follow-up, overall differences with controls were maintained one year later. In conclusion, we found no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.
Bouso, J. C, González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., … Riba, J. (2012). Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study. PLoS ONE 7(8), 1-13. http://dx.doi.org/10.1371/journal.pone.0042421
Link to full text
Dr. Grof’s consciousness research over the last five decades has shown that the deepest roots of trauma often lie in experiences from birth or in events from human history that have not yet been resolved and are still active in the collective unconscious. This unresolved personal or collective history then expresses through an individual or group that has some connection to the earlier events. Traditional therapeutic approaches which focus only on events in the personal biography or tranquilizing medications do not access or heal these deeper wounds in the human psyche. From a more general perspective, Dr. Grof examines the broad problems of violence and greed in society and finds that the widespread fear and aggression between individuals and groups may also originate in large part from the unconscious acting-out of unresolved historical traumas from the collective unconscious. The message of Dr. Grof and this book is, however, a hopeful one: there are approaches to therapy which utilize a specific non-ordinary state of consciousness which enables individuals, with support, to access and heal these deeper levels of trauma from the personal and collective unconscious. He has named this state of consciousness Holotropic, a composite word which means “oriented toward wholeness” or “moving in the direction of wholeness” (from the Greek holos = whole and trepo, trepein = moving toward or in the direction of something). Dr. Grof describes various approaches to achieving this Holotropic state and using it for healing, with his focus on Holotropic Breathwork, which he developed with his partner Christina, and psychedelic therapy, which he pioneered in the 1950s and which is now experiencing a renaissance of clinical research for treatment of addictions and PTSD.